United Asset Strategies, Inc. Akari Therapeutics PLC Transaction History

United Asset Strategies, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 19, 2021	SELL	$1.69 - $2.85 $489,669 - $825,773	-289,745 Closed	0 $0
Q1 2021 Apr 27, 2021	BUY	$1.81 - $3.88 $5,672 - $12,159	3,134 Added 1.09%	289,745 $765,000
Q3 2020 Nov 03, 2020	SELL	$1.58 - $2.37 $21,154 - $31,731	-13,389 Reduced 4.46%	286,611 $499,000
Q2 2020 Aug 03, 2020	BUY	$1.16 - $2.61 $348,000 - $783,000	300,000 New	300,000 $654,000

Ticker AKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,349,200
Market Cap $68.8M
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...

Get notified when there are updates to the investment portfolio of United Asset Strategies, Inc., based on Form 13F filings with the SEC.

Stay updated on United Asset Strategies, Inc. with notifications on news.